Urinary Tract Infection Treatment Market

Urinary Tract Infection Treatment Market Forecast
to 2026 with Key Companies Profile, Supply and
Growth Factors
Urinary Tract Infection (UTI) is caused when bacteria enters the urethra and infects the urinary
bladder, causing severe health issues. UTI infections are common health problems in females
than in males with biologic factors accounting as the major cause. Antibiotics are usually the
first line of treatment prescribed by doctors for urinary tract infections. According to the site of
manifestation by the microbe, infections are classified as cystitis (bladder), urethritis (urethra),
prostatitis (prostate) or pyelonephritis (kidney). Painful and increased frequency of urination,
excessive and involuntary passing of urine at night are the common symptoms associated with
UTI. Hospitalized patients using urinary catheters are at a higher risk for developing UTI.
Request PDF Brochure Of Research Report:
https://www.coherentmarketinsights.com/insight/request-pdf/1178
Increasing prevalence of recurring urinary infections is expected to boost growth of the urinary
tract infection treatment market
Rise in chronic kidney diseases and increasing use of urinary catheterization is leading to
development of urinary infections and this is expected to be major growth drivers for urinary
tract infection market. According to the Centers of Disease Control and Prevention, 2016,
UTIs are the most common bacterial infections globally, affecting 150 million people every year.
Furthermore, about 10 in 25 women and 3 in 25 men are estimated to have symptoms of at
least one UTI during their lifetime. According to the study by Sultan Qaboos University Medical
Journal, 2013, around 50–60% of women report at least one UTI in their lifetime, and one in
three will have at least one symptomatic UTI necessitating antibiotic treatment by age 24. Also,
patients with diabetes have a higher frequency of UTIs, due to the presence of long-term
complications of diabetes such as neuropathy. According to the American Diabetes Association,
in 2017, 9.4% of the people diagnosed with type 2 diabetes had a UTI compared to only 5.7%
of people without diabetes.
Approval of combination products for improving indications of existing drugs and to combat
multi-drug resistant bacteria are some key factors positively affecting market growth. For
instance, in 2015, FDA approved Avycaz (ceftazidime and avibactam) for complicated abdominal
and urinary tract infections in combination with metronidazole that has limited or no
alternative treatment options.
Report includes chapters which deeply display the following deliverable about industry :
• Urinary Tract Infection Treatment Market Research Objective and Assumption
• Urinary Tract Infection Treatment Market Purview - Report Description, Executive Summary,
and Coherent Opportunity Map (COM)
• Urinary Tract Infection Treatment Market Dynamics, Regulations, and Trends Analysis Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Urinary Tract Infection Treatment Market, By Regions
• Urinary Tract Infection Treatment Market Competition by Manufacturers including Production,
Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Urinary Tract Infection Treatment Market Manufacturers Profiles/Analysis including Company
Basic Information, Manufacturing Base and Its Competitors.
• Urinary Tract Infection Treatment Market Manufacturing Cost Analysis including Key Raw
Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Urinary Tract Infection Treatment Market Forecast including Production, Consumption, Import
and Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
To Get Instant Access, Purchase Report Here @ https://www.coherentmarketinsights.com/insight/
buy-now/1178
Strategic collaborations is the strategy adopted by key players in the market to enhance its
presence and for new drug development
Strategy of leading players is to achieve growth through mergers & acquisitions and
collaborations. In 2016, GlaxoSmithKline and Fimbrion Therapeutics, Inc., entered into a
collaboration, which is focused on preclinical development of mannose-containing small
molecule compounds called mannosides for the treatment and prevention of urinary tract
infections.
Key players operating in the urinary tract infection treatment market include Cipla Ltd.,
Johnson & Johnson, Bayer AG, Pfizer Inc., GlaxoSmithKline, Boehringer Ingelheim, F.
Hoffmann-La Roche Ltd., Novartis AG AstraZeneca Plc, and Roche Ltd.
Browse Complete Report For More Information @
https://www.coherentmarketinsights.com/ongoing-insight/urinary-tract-infection-treatment-market1178
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Urinary Tract Infection (UTI) is caused when bacteria enters the urethra and infects the urinary bladder, causing severe health issues.

Download Report